ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1466

Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis

Klára Prajzlerová1, Olga Kryštůfková2, Petra Hánová1, Hana Hulejová3, Monika Gregová4, Karel Pavelka4, Jiri Vencovsky1, Ladislav Šenolt5 and Mária Filková1, 1Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, 2Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, prague, Czech Republic, 3Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, 4Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, monocytes, natural killer (NK) cells, rheumatoid arthritis (RA) and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anti-citrullinated protein antibodies (ACPA) are detectable long before the manifestation of rheumatoid arthritis (RA). EULAR provided a clinical definition of individuals with arthralgia suspicious for progression to RA (clinically suspect arthralgia, CSA). The alteration of monocyte subpopulations in patients with established RA has been described. We aimed to evaluate possible predictive value of the monocyte and lymphocyte subpopulations in individuals in the preclinical phase of RA.

Methods:

Thirty-four individuals with arthralgia (mean age 45.11±12.6 years; 91% females) and 80 age and gender matched healthy controls (HC) were included. Leukocytes from peripheral blood were analysed by flow cytometry. Lymphocyte subpopulations were defined as CD19+CD3-, CD3+CD4+, CD3+CD8+ and CD16/56+CD3- (NK) cells, monocytes were segregated into classical (CD14+CD16-), intermediate (CD14+CD16+/++) and non-classical (CD14-/dimCD16++) subsets. Data were analysed using t-test and Spearman’s correlation and are expressed as median and interquartile range (IQR).

Results:

Out of 34 patients with arthralgia, 27 were ACPA+ and 17 met CSA definition (10 of them were ACPA+), with symptoms duration 36 months (IQR: 77.5), CRP 2.27 mg/L (IQR 3.35), DAS28 2.13 (IQR 1.32). As per definition, there was no clinical synovitis at baseline. Five individuals developed RA within 3-9 months of follow up.

Patients with arthralgia had higher %CD3+ (p=0.002) and %CD3+CD8+ (p=0.034) T cells and lower %NK (p=0.003) and absolute count of NK cells (p=0.002) compared to HC. This was confirmed in a subgroup of ACPA+ patients. The count of tender joints correlated positively with %CD3 (p=0.009; r=0.491) and %CD3CD8 (p=0.034; r=0.410) T cells and negatively with %NK cells (p=0.019; r=0.045). Moreover, individuals who developed RA during follow up, had higher baseline %CD3+ cells (p=0.046) with the trend for lower %NK cells (p=0.065). No differences were seen between patients meeting CSA definition and non-CSA individuals.

Expansion of intermediate (p=0.012) and non-classical (p=0.007) monocytes with reduction of classical monocytes (p=0.001) were demonstrated in all patients with arthralgia compared to HC. Importantly, ACPA+ patients had higher non-classical (p=0.041) and lower classical monocytes (p=0.022) than ACPA- patients. Similarly, ACPA+ patients had higher intermediate (p=0.006) or non-classical (p=0.012) and lower classical (p=0.004) monocytes compared to HC, while no differences were seen between ACPA- patients and HC.

Conclusion:

We demonstrate lower NK cells, expansion of intermediate and non-classical monocyte subpopulation in patients in the preclinical phase of RA, especially in ACPA+ individuals. Since this pattern has been described so far in patients with established RA, our data suggest their role even in early phases of RA development. These leukocyte subpopulations could be considered as prognostic biomarkers for further development of RA.

Acknowledgement: Projects AZV-17-32612A and MHCR 023728.


Disclosure: K. Prajzlerová, None; O. Kryštůfková, None; P. Hánová, None; H. Hulejová, None; M. Gregová, None; K. Pavelka, None; J. Vencovsky, None; L. Šenolt, None; M. Filková, None.

To cite this abstract in AMA style:

Prajzlerová K, Kryštůfková O, Hánová P, Hulejová H, Gregová M, Pavelka K, Vencovsky J, Šenolt L, Filková M. Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/altered-count-of-nk-cells-and-non-classical-monocyte-subpopulation-in-the-pre-clinical-phase-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-count-of-nk-cells-and-non-classical-monocyte-subpopulation-in-the-pre-clinical-phase-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology